Review



control peptide (cp-3  (AnaSpec)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    AnaSpec control peptide (cp-3
    MUC1 inhibition leads to decrease in PD-L1 expression. MUC1 was silenced in MOLM-14 and THP-1 AML cells using lentiviral shRNA hairpin against MUC1. As a control, MOLM-14 cells were infected with control shRNA. The cells were then evaluated for PD-L1 expression using (a) flow cytometry and (b) western blot analysis. (c) Tumor cells were obtained from patients with AML at diagnosis. The cells were then treated with 2.5 µm MUC1 inhibitor, GO-203 daily for 3 days. As a control the cells were treated with control peptide <t>CP-3.</t> Subsequently, the cells underwent western blot analysis for PD-L1 expression. Representative blots from patients AML1 and AML2 are shown (n =3). (d) A representative experiment demonstrating PD-L1 mRNA levels, in MUC1-silenced MOLM-14 and THP-1 cells evaluated using qPCR. Each condition was performed in triplicate (P<0.05; n=2).
    Control Peptide (Cp 3, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/control peptide (cp-3/product/AnaSpec
    Average 90 stars, based on 1 article reviews
    control peptide (cp-3 - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs"

    Article Title: MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs

    Journal: Leukemia

    doi: 10.1038/leu.2017.163

    MUC1 inhibition leads to decrease in PD-L1 expression. MUC1 was silenced in MOLM-14 and THP-1 AML cells using lentiviral shRNA hairpin against MUC1. As a control, MOLM-14 cells were infected with control shRNA. The cells were then evaluated for PD-L1 expression using (a) flow cytometry and (b) western blot analysis. (c) Tumor cells were obtained from patients with AML at diagnosis. The cells were then treated with 2.5 µm MUC1 inhibitor, GO-203 daily for 3 days. As a control the cells were treated with control peptide CP-3. Subsequently, the cells underwent western blot analysis for PD-L1 expression. Representative blots from patients AML1 and AML2 are shown (n =3). (d) A representative experiment demonstrating PD-L1 mRNA levels, in MUC1-silenced MOLM-14 and THP-1 cells evaluated using qPCR. Each condition was performed in triplicate (P<0.05; n=2).
    Figure Legend Snippet: MUC1 inhibition leads to decrease in PD-L1 expression. MUC1 was silenced in MOLM-14 and THP-1 AML cells using lentiviral shRNA hairpin against MUC1. As a control, MOLM-14 cells were infected with control shRNA. The cells were then evaluated for PD-L1 expression using (a) flow cytometry and (b) western blot analysis. (c) Tumor cells were obtained from patients with AML at diagnosis. The cells were then treated with 2.5 µm MUC1 inhibitor, GO-203 daily for 3 days. As a control the cells were treated with control peptide CP-3. Subsequently, the cells underwent western blot analysis for PD-L1 expression. Representative blots from patients AML1 and AML2 are shown (n =3). (d) A representative experiment demonstrating PD-L1 mRNA levels, in MUC1-silenced MOLM-14 and THP-1 cells evaluated using qPCR. Each condition was performed in triplicate (P<0.05; n=2).

    Techniques Used: Inhibition, Expressing, shRNA, Infection, Flow Cytometry, Western Blot

    miR-34a and miR-200c regulate PD-L1 expression in AML cells. (a) The seed sequences of miR-34a and miR-200c on the 3′-UTR PD-L1, transcript variant 1, NM_014143.3, were identified by RegRNA: a regulatory RNA motifs and element web server. MUC1 was silenced in MOLM-14 cells using the CRISPR/Cas9 technology and in THP-1 cells using transduction with MUC1-specific shRNA. (b) Relative levels of miR-34a were detected in MOLM-14 and THP-1 cells using qPCR. miR-34a was overexpressed in MOLM-14 and THP-1 cells using lentiviral transduction. (c) PD-L1 levels were evaluated using western blot analysis in miR-34a overexpressed or control MOLM-14 and THP-1 AML cells. (d) Relative levels of miR-200c were detected in MOLM-14 and THP-1 cells using qPCR. MiR-200c was overexpressed in MOLM-14 cells using lentiviral transduction. PD-L1 levels were evaluated in control and miR-200c overexpressed cells using (e) western blotting and (f) flow cytometry. Tumor cells were obtained from PB or BM aspirated of patients with AML at diagnosis. The cells were then treated with 2.5 µm MUC1 inhibitor, GO-203 daily for 3 days. As a control the cells were treated with control peptide CP-3. (g) Subsequently, relative levels of miR-34a and miR200c were detected in these cells compared to controls using qPCR. Three patients were evaluated, the bar graphs represent patients AML2 and AML3 (P<0.05).
    Figure Legend Snippet: miR-34a and miR-200c regulate PD-L1 expression in AML cells. (a) The seed sequences of miR-34a and miR-200c on the 3′-UTR PD-L1, transcript variant 1, NM_014143.3, were identified by RegRNA: a regulatory RNA motifs and element web server. MUC1 was silenced in MOLM-14 cells using the CRISPR/Cas9 technology and in THP-1 cells using transduction with MUC1-specific shRNA. (b) Relative levels of miR-34a were detected in MOLM-14 and THP-1 cells using qPCR. miR-34a was overexpressed in MOLM-14 and THP-1 cells using lentiviral transduction. (c) PD-L1 levels were evaluated using western blot analysis in miR-34a overexpressed or control MOLM-14 and THP-1 AML cells. (d) Relative levels of miR-200c were detected in MOLM-14 and THP-1 cells using qPCR. MiR-200c was overexpressed in MOLM-14 cells using lentiviral transduction. PD-L1 levels were evaluated in control and miR-200c overexpressed cells using (e) western blotting and (f) flow cytometry. Tumor cells were obtained from PB or BM aspirated of patients with AML at diagnosis. The cells were then treated with 2.5 µm MUC1 inhibitor, GO-203 daily for 3 days. As a control the cells were treated with control peptide CP-3. (g) Subsequently, relative levels of miR-34a and miR200c were detected in these cells compared to controls using qPCR. Three patients were evaluated, the bar graphs represent patients AML2 and AML3 (P<0.05).

    Techniques Used: Expressing, Variant Assay, CRISPR, Transduction, shRNA, Western Blot, Flow Cytometry



    Similar Products

    control peptide (cp-3  (AnaSpec)
    90
    AnaSpec control peptide (cp-3
    MUC1 inhibition leads to decrease in PD-L1 expression. MUC1 was silenced in MOLM-14 and THP-1 AML cells using lentiviral shRNA hairpin against MUC1. As a control, MOLM-14 cells were infected with control shRNA. The cells were then evaluated for PD-L1 expression using (a) flow cytometry and (b) western blot analysis. (c) Tumor cells were obtained from patients with AML at diagnosis. The cells were then treated with 2.5 µm MUC1 inhibitor, GO-203 daily for 3 days. As a control the cells were treated with control peptide <t>CP-3.</t> Subsequently, the cells underwent western blot analysis for PD-L1 expression. Representative blots from patients AML1 and AML2 are shown (n =3). (d) A representative experiment demonstrating PD-L1 mRNA levels, in MUC1-silenced MOLM-14 and THP-1 cells evaluated using qPCR. Each condition was performed in triplicate (P<0.05; n=2).
    Control Peptide (Cp 3, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/control peptide (cp-3/product/AnaSpec
    Average 90 stars, based on 1 article reviews
    control peptide (cp-3 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    control peptide cp-3  (AnaSpec)
    90
    AnaSpec control peptide cp-3
    MUC1 inhibition leads to decrease in PD-L1 expression. MUC1 was silenced in MOLM-14 and THP-1 AML cells using lentiviral shRNA hairpin against MUC1. As a control, MOLM-14 cells were infected with control shRNA. The cells were then evaluated for PD-L1 expression using (a) flow cytometry and (b) western blot analysis. (c) Tumor cells were obtained from patients with AML at diagnosis. The cells were then treated with 2.5 µm MUC1 inhibitor, GO-203 daily for 3 days. As a control the cells were treated with control peptide <t>CP-3.</t> Subsequently, the cells underwent western blot analysis for PD-L1 expression. Representative blots from patients AML1 and AML2 are shown (n =3). (d) A representative experiment demonstrating PD-L1 mRNA levels, in MUC1-silenced MOLM-14 and THP-1 cells evaluated using qPCR. Each condition was performed in triplicate (P<0.05; n=2).
    Control Peptide Cp 3, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/control peptide cp-3/product/AnaSpec
    Average 90 stars, based on 1 article reviews
    control peptide cp-3 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    MUC1 inhibition leads to decrease in PD-L1 expression. MUC1 was silenced in MOLM-14 and THP-1 AML cells using lentiviral shRNA hairpin against MUC1. As a control, MOLM-14 cells were infected with control shRNA. The cells were then evaluated for PD-L1 expression using (a) flow cytometry and (b) western blot analysis. (c) Tumor cells were obtained from patients with AML at diagnosis. The cells were then treated with 2.5 µm MUC1 inhibitor, GO-203 daily for 3 days. As a control the cells were treated with control peptide CP-3. Subsequently, the cells underwent western blot analysis for PD-L1 expression. Representative blots from patients AML1 and AML2 are shown (n =3). (d) A representative experiment demonstrating PD-L1 mRNA levels, in MUC1-silenced MOLM-14 and THP-1 cells evaluated using qPCR. Each condition was performed in triplicate (P<0.05; n=2).

    Journal: Leukemia

    Article Title: MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs

    doi: 10.1038/leu.2017.163

    Figure Lengend Snippet: MUC1 inhibition leads to decrease in PD-L1 expression. MUC1 was silenced in MOLM-14 and THP-1 AML cells using lentiviral shRNA hairpin against MUC1. As a control, MOLM-14 cells were infected with control shRNA. The cells were then evaluated for PD-L1 expression using (a) flow cytometry and (b) western blot analysis. (c) Tumor cells were obtained from patients with AML at diagnosis. The cells were then treated with 2.5 µm MUC1 inhibitor, GO-203 daily for 3 days. As a control the cells were treated with control peptide CP-3. Subsequently, the cells underwent western blot analysis for PD-L1 expression. Representative blots from patients AML1 and AML2 are shown (n =3). (d) A representative experiment demonstrating PD-L1 mRNA levels, in MUC1-silenced MOLM-14 and THP-1 cells evaluated using qPCR. Each condition was performed in triplicate (P<0.05; n=2).

    Article Snippet: AML cells were treated once daily with 2.5 µ m MUC1-C inhibitor peptide (GO-203) or a control peptide (CP-3) (AnaSpec) for 3 days.

    Techniques: Inhibition, Expressing, shRNA, Infection, Flow Cytometry, Western Blot

    miR-34a and miR-200c regulate PD-L1 expression in AML cells. (a) The seed sequences of miR-34a and miR-200c on the 3′-UTR PD-L1, transcript variant 1, NM_014143.3, were identified by RegRNA: a regulatory RNA motifs and element web server. MUC1 was silenced in MOLM-14 cells using the CRISPR/Cas9 technology and in THP-1 cells using transduction with MUC1-specific shRNA. (b) Relative levels of miR-34a were detected in MOLM-14 and THP-1 cells using qPCR. miR-34a was overexpressed in MOLM-14 and THP-1 cells using lentiviral transduction. (c) PD-L1 levels were evaluated using western blot analysis in miR-34a overexpressed or control MOLM-14 and THP-1 AML cells. (d) Relative levels of miR-200c were detected in MOLM-14 and THP-1 cells using qPCR. MiR-200c was overexpressed in MOLM-14 cells using lentiviral transduction. PD-L1 levels were evaluated in control and miR-200c overexpressed cells using (e) western blotting and (f) flow cytometry. Tumor cells were obtained from PB or BM aspirated of patients with AML at diagnosis. The cells were then treated with 2.5 µm MUC1 inhibitor, GO-203 daily for 3 days. As a control the cells were treated with control peptide CP-3. (g) Subsequently, relative levels of miR-34a and miR200c were detected in these cells compared to controls using qPCR. Three patients were evaluated, the bar graphs represent patients AML2 and AML3 (P<0.05).

    Journal: Leukemia

    Article Title: MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs

    doi: 10.1038/leu.2017.163

    Figure Lengend Snippet: miR-34a and miR-200c regulate PD-L1 expression in AML cells. (a) The seed sequences of miR-34a and miR-200c on the 3′-UTR PD-L1, transcript variant 1, NM_014143.3, were identified by RegRNA: a regulatory RNA motifs and element web server. MUC1 was silenced in MOLM-14 cells using the CRISPR/Cas9 technology and in THP-1 cells using transduction with MUC1-specific shRNA. (b) Relative levels of miR-34a were detected in MOLM-14 and THP-1 cells using qPCR. miR-34a was overexpressed in MOLM-14 and THP-1 cells using lentiviral transduction. (c) PD-L1 levels were evaluated using western blot analysis in miR-34a overexpressed or control MOLM-14 and THP-1 AML cells. (d) Relative levels of miR-200c were detected in MOLM-14 and THP-1 cells using qPCR. MiR-200c was overexpressed in MOLM-14 cells using lentiviral transduction. PD-L1 levels were evaluated in control and miR-200c overexpressed cells using (e) western blotting and (f) flow cytometry. Tumor cells were obtained from PB or BM aspirated of patients with AML at diagnosis. The cells were then treated with 2.5 µm MUC1 inhibitor, GO-203 daily for 3 days. As a control the cells were treated with control peptide CP-3. (g) Subsequently, relative levels of miR-34a and miR200c were detected in these cells compared to controls using qPCR. Three patients were evaluated, the bar graphs represent patients AML2 and AML3 (P<0.05).

    Article Snippet: AML cells were treated once daily with 2.5 µ m MUC1-C inhibitor peptide (GO-203) or a control peptide (CP-3) (AnaSpec) for 3 days.

    Techniques: Expressing, Variant Assay, CRISPR, Transduction, shRNA, Western Blot, Flow Cytometry